Thejus Jayakrishnan, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anus Neoplasms | 2 | 2024 | 336 | 0.840 |
Why?
|
Biliary Tract Neoplasms | 1 | 2024 | 187 | 0.810 |
Why?
|
Desmoplastic Small Round Cell Tumor | 1 | 2021 | 33 | 0.750 |
Why?
|
Henipavirus Infections | 1 | 2020 | 7 | 0.730 |
Why?
|
Nipah Virus | 1 | 2020 | 12 | 0.730 |
Why?
|
Healthcare Disparities | 5 | 2020 | 3421 | 0.720 |
Why?
|
Patient Protection and Affordable Care Act | 2 | 2020 | 1189 | 0.710 |
Why?
|
Immunization Programs | 2 | 2013 | 267 | 0.670 |
Why?
|
Age of Onset | 2 | 2024 | 3346 | 0.640 |
Why?
|
Resource Allocation | 1 | 2020 | 354 | 0.600 |
Why?
|
Pancreatic Neoplasms | 3 | 2023 | 5443 | 0.570 |
Why?
|
Orchiectomy | 1 | 2019 | 466 | 0.570 |
Why?
|
Chemotherapy, Cancer, Regional Perfusion | 2 | 2014 | 94 | 0.560 |
Why?
|
Burkitt Lymphoma | 1 | 2019 | 338 | 0.560 |
Why?
|
Pasteurella multocida | 1 | 2016 | 5 | 0.550 |
Why?
|
Pasteurella Infections | 1 | 2016 | 8 | 0.550 |
Why?
|
Peritoneal Neoplasms | 5 | 2015 | 714 | 0.540 |
Why?
|
Faculty, Medical | 3 | 2014 | 1225 | 0.530 |
Why?
|
Physician Executives | 2 | 2014 | 140 | 0.530 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2020 | 526 | 0.520 |
Why?
|
Adenocarcinoma | 4 | 2023 | 6401 | 0.520 |
Why?
|
Lymphoma | 2 | 2023 | 1900 | 0.480 |
Why?
|
Laparoscopy | 4 | 2015 | 2055 | 0.470 |
Why?
|
Hyperthermia, Induced | 3 | 2015 | 416 | 0.470 |
Why?
|
Multiple Myeloma | 3 | 2022 | 5195 | 0.460 |
Why?
|
Metabolomics | 1 | 2024 | 1675 | 0.460 |
Why?
|
Gallbladder Neoplasms | 2 | 2014 | 190 | 0.460 |
Why?
|
India | 8 | 2020 | 2325 | 0.460 |
Why?
|
Cholecystostomy | 1 | 2014 | 54 | 0.450 |
Why?
|
Empyema | 1 | 2013 | 41 | 0.450 |
Why?
|
Cholecystitis, Acute | 1 | 2014 | 81 | 0.430 |
Why?
|
Testicular Neoplasms | 1 | 2019 | 805 | 0.430 |
Why?
|
Research Support as Topic | 2 | 2014 | 696 | 0.420 |
Why?
|
Cholecystitis | 1 | 2013 | 181 | 0.410 |
Why?
|
Biliary Tract Diseases | 1 | 2013 | 159 | 0.410 |
Why?
|
Insurance Coverage | 2 | 2020 | 1946 | 0.400 |
Why?
|
Cholelithiasis | 1 | 2013 | 408 | 0.390 |
Why?
|
Health Status Disparities | 2 | 2021 | 1886 | 0.390 |
Why?
|
Cholecystectomy | 1 | 2014 | 409 | 0.390 |
Why?
|
National Institutes of Health (U.S.) | 2 | 2014 | 794 | 0.380 |
Why?
|
Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2012 | 39 | 0.380 |
Why?
|
Rectal Neoplasms | 1 | 2020 | 1183 | 0.380 |
Why?
|
Blood Vessel Prosthesis | 1 | 2016 | 957 | 0.370 |
Why?
|
Whooping Cough | 1 | 2012 | 87 | 0.370 |
Why?
|
Prosthesis-Related Infections | 1 | 2016 | 497 | 0.360 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2021 | 11886 | 0.350 |
Why?
|
Immunization Schedule | 1 | 2011 | 228 | 0.340 |
Why?
|
Health Policy | 2 | 2013 | 2700 | 0.330 |
Why?
|
Mass Vaccination | 1 | 2011 | 111 | 0.330 |
Why?
|
Colonic Neoplasms | 2 | 2020 | 2543 | 0.320 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2020 | 1756 | 0.320 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2024 | 4064 | 0.310 |
Why?
|
Schools, Medical | 2 | 2014 | 882 | 0.310 |
Why?
|
Health Care Rationing | 1 | 2012 | 435 | 0.310 |
Why?
|
Product Labeling | 1 | 2009 | 76 | 0.310 |
Why?
|
Audiovisual Aids | 1 | 2009 | 99 | 0.300 |
Why?
|
Socioeconomic Factors | 5 | 2023 | 7860 | 0.300 |
Why?
|
Tobacco, Smokeless | 1 | 2009 | 133 | 0.300 |
Why?
|
Colorectal Neoplasms | 3 | 2024 | 6982 | 0.280 |
Why?
|
Health Personnel | 1 | 2020 | 3382 | 0.270 |
Why?
|
Aortic Aneurysm, Abdominal | 1 | 2016 | 1252 | 0.270 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2016 | 1459 | 0.260 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2021 | 1793 | 0.260 |
Why?
|
Vaccines | 2 | 2013 | 842 | 0.260 |
Why?
|
Suicide | 1 | 2016 | 1606 | 0.240 |
Why?
|
Common Bile Duct Neoplasms | 2 | 2014 | 121 | 0.230 |
Why?
|
Ampulla of Vater | 2 | 2014 | 150 | 0.220 |
Why?
|
Citrates | 1 | 2024 | 134 | 0.220 |
Why?
|
Citric Acid | 1 | 2024 | 124 | 0.220 |
Why?
|
Disease Management | 1 | 2014 | 2537 | 0.210 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2024 | 213 | 0.210 |
Why?
|
Stomach Neoplasms | 1 | 2013 | 1483 | 0.210 |
Why?
|
Macroglossia | 1 | 2022 | 12 | 0.210 |
Why?
|
Humans | 48 | 2024 | 768887 | 0.210 |
Why?
|
Education, Medical, Undergraduate | 1 | 2012 | 1085 | 0.210 |
Why?
|
Endovascular Procedures | 1 | 2016 | 2218 | 0.200 |
Why?
|
Crime | 1 | 2003 | 206 | 0.200 |
Why?
|
Biomedical Research | 2 | 2014 | 3463 | 0.190 |
Why?
|
Evidence-Based Medicine | 1 | 2013 | 3709 | 0.180 |
Why?
|
Middle Aged | 19 | 2024 | 223740 | 0.180 |
Why?
|
Leukemoid Reaction | 1 | 2020 | 18 | 0.180 |
Why?
|
Leg Ulcer | 1 | 2020 | 71 | 0.180 |
Why?
|
Male | 25 | 2024 | 365249 | 0.170 |
Why?
|
Arginine | 1 | 2024 | 932 | 0.170 |
Why?
|
Education, Medical, Graduate | 1 | 2012 | 2422 | 0.170 |
Why?
|
Breast Neoplasms, Male | 1 | 2021 | 212 | 0.160 |
Why?
|
Paraneoplastic Syndromes | 1 | 2020 | 154 | 0.160 |
Why?
|
Combined Modality Therapy | 5 | 2023 | 8559 | 0.160 |
Why?
|
Neoplasms | 3 | 2023 | 22390 | 0.160 |
Why?
|
Neoplasm Staging | 6 | 2021 | 11262 | 0.160 |
Why?
|
Kaplan-Meier Estimate | 5 | 2021 | 6546 | 0.160 |
Why?
|
Databases, Factual | 6 | 2021 | 8095 | 0.150 |
Why?
|
Living Donors | 1 | 2003 | 649 | 0.150 |
Why?
|
Prognosis | 6 | 2020 | 30044 | 0.140 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2020 | 271 | 0.140 |
Why?
|
Hepatic Artery | 2 | 2015 | 232 | 0.140 |
Why?
|
Pets | 1 | 2016 | 47 | 0.130 |
Why?
|
Retrospective Studies | 11 | 2021 | 81892 | 0.130 |
Why?
|
Acute Disease | 2 | 2019 | 7245 | 0.130 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2021 | 9442 | 0.130 |
Why?
|
Mastectomy, Segmental | 1 | 2021 | 960 | 0.130 |
Why?
|
Zoonoses | 1 | 2016 | 180 | 0.120 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2020 | 454 | 0.120 |
Why?
|
Academic Medical Centers | 3 | 2015 | 2784 | 0.120 |
Why?
|
Female | 21 | 2024 | 397464 | 0.120 |
Why?
|
Herpesvirus 4, Human | 1 | 2020 | 1082 | 0.120 |
Why?
|
Tissue and Organ Procurement | 1 | 2003 | 986 | 0.120 |
Why?
|
Aortography | 1 | 2016 | 422 | 0.120 |
Why?
|
Amyloidosis | 1 | 2022 | 879 | 0.120 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2020 | 617 | 0.110 |
Why?
|
Morbidity | 2 | 2016 | 1757 | 0.110 |
Why?
|
HIV Infections | 1 | 2020 | 17589 | 0.110 |
Why?
|
Aged | 10 | 2024 | 171790 | 0.110 |
Why?
|
United States | 9 | 2021 | 73180 | 0.110 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2014 | 304 | 0.110 |
Why?
|
Cost-Benefit Analysis | 3 | 2016 | 5544 | 0.100 |
Why?
|
Rhabdomyosarcoma | 1 | 2015 | 358 | 0.100 |
Why?
|
Efficiency, Organizational | 2 | 2014 | 699 | 0.100 |
Why?
|
Rotavirus Vaccines | 1 | 2013 | 62 | 0.100 |
Why?
|
Decision Trees | 1 | 2014 | 509 | 0.100 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2015 | 335 | 0.100 |
Why?
|
Smoking | 1 | 2009 | 9094 | 0.100 |
Why?
|
Breeding | 1 | 2011 | 49 | 0.100 |
Why?
|
Survival Analysis | 3 | 2020 | 10115 | 0.100 |
Why?
|
Treatment Outcome | 8 | 2020 | 65485 | 0.100 |
Why?
|
Rubella Vaccine | 1 | 2011 | 23 | 0.100 |
Why?
|
Haemophilus Vaccines | 1 | 2011 | 71 | 0.090 |
Why?
|
Pancreaticoduodenectomy | 1 | 2014 | 516 | 0.090 |
Why?
|
Guideline Adherence | 1 | 2021 | 2240 | 0.090 |
Why?
|
Disease Outbreaks | 1 | 2020 | 1761 | 0.090 |
Why?
|
Tumor Microenvironment | 1 | 2024 | 3951 | 0.090 |
Why?
|
Insect Vectors | 1 | 2011 | 136 | 0.090 |
Why?
|
Drainage | 1 | 2016 | 1184 | 0.090 |
Why?
|
Aedes | 1 | 2011 | 101 | 0.090 |
Why?
|
Intestinal Obstruction | 1 | 2014 | 433 | 0.090 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 1560 | 0.090 |
Why?
|
Hepatectomy | 1 | 2014 | 588 | 0.090 |
Why?
|
Esophageal Neoplasms | 1 | 2020 | 1674 | 0.090 |
Why?
|
Publishing | 2 | 2014 | 837 | 0.090 |
Why?
|
Catheterization, Central Venous | 1 | 2015 | 536 | 0.090 |
Why?
|
Hepatitis B Vaccines | 1 | 2011 | 178 | 0.080 |
Why?
|
Molecular Targeted Therapy | 1 | 2021 | 2830 | 0.080 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2014 | 3554 | 0.080 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2024 | 5342 | 0.080 |
Why?
|
Liver Neoplasms | 2 | 2015 | 4363 | 0.080 |
Why?
|
Cholangiocarcinoma | 1 | 2014 | 562 | 0.080 |
Why?
|
Bile Duct Neoplasms | 1 | 2014 | 615 | 0.080 |
Why?
|
Operating Rooms | 1 | 2015 | 793 | 0.080 |
Why?
|
Specialties, Surgical | 1 | 2013 | 393 | 0.080 |
Why?
|
Aged, 80 and over | 5 | 2021 | 59738 | 0.080 |
Why?
|
Lymph Node Excision | 1 | 2014 | 1273 | 0.080 |
Why?
|
Immunotherapy | 1 | 2024 | 4755 | 0.080 |
Why?
|
Mesothelioma | 1 | 2014 | 811 | 0.070 |
Why?
|
Kidney Transplantation | 1 | 2003 | 4265 | 0.070 |
Why?
|
Radiography, Interventional | 1 | 2015 | 1131 | 0.070 |
Why?
|
Drug Costs | 1 | 2016 | 1198 | 0.070 |
Why?
|
Quality-Adjusted Life Years | 1 | 2014 | 1741 | 0.070 |
Why?
|
Time Factors | 4 | 2016 | 40266 | 0.070 |
Why?
|
Adult | 9 | 2024 | 223818 | 0.070 |
Why?
|
Pneumococcal Vaccines | 1 | 2011 | 414 | 0.070 |
Why?
|
Recurrence | 1 | 2019 | 8512 | 0.070 |
Why?
|
Papillomavirus Vaccines | 1 | 2013 | 497 | 0.070 |
Why?
|
Medicaid | 1 | 2020 | 2843 | 0.070 |
Why?
|
Age Factors | 3 | 2021 | 18454 | 0.070 |
Why?
|
Population Surveillance | 1 | 2016 | 2597 | 0.060 |
Why?
|
Lung Neoplasms | 4 | 2020 | 13593 | 0.060 |
Why?
|
Multivariate Analysis | 2 | 2016 | 12093 | 0.060 |
Why?
|
Water | 1 | 2011 | 1421 | 0.060 |
Why?
|
Cost of Illness | 1 | 2014 | 1959 | 0.060 |
Why?
|
Ovarian Neoplasms | 1 | 2021 | 4919 | 0.060 |
Why?
|
Chemoembolization, Therapeutic | 2 | 2015 | 128 | 0.060 |
Why?
|
Decision Support Techniques | 1 | 2014 | 2008 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 1 | 2019 | 5707 | 0.050 |
Why?
|
Legislation, Medical | 1 | 2003 | 99 | 0.050 |
Why?
|
Professional Misconduct | 1 | 2003 | 72 | 0.050 |
Why?
|
Neoadjuvant Therapy | 1 | 2014 | 2909 | 0.050 |
Why?
|
Carcinoma | 1 | 2014 | 2340 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2020 | 5520 | 0.050 |
Why?
|
Sex Factors | 1 | 2016 | 10641 | 0.050 |
Why?
|
Follow-Up Studies | 4 | 2021 | 39394 | 0.050 |
Why?
|
Anti-Bacterial Agents | 2 | 2020 | 7472 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 5434 | 0.050 |
Why?
|
Patient Selection | 3 | 2023 | 4265 | 0.050 |
Why?
|
Ultrasonography | 1 | 2014 | 6001 | 0.040 |
Why?
|
Leukapheresis | 1 | 2020 | 150 | 0.040 |
Why?
|
Propensity Score | 2 | 2021 | 1968 | 0.040 |
Why?
|
Remission, Spontaneous | 1 | 2020 | 385 | 0.040 |
Why?
|
Endarterectomy | 1 | 2020 | 196 | 0.040 |
Why?
|
Infant | 2 | 2013 | 36541 | 0.040 |
Why?
|
Decision Making | 1 | 2013 | 3952 | 0.040 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2020 | 283 | 0.040 |
Why?
|
Risk Factors | 5 | 2021 | 74971 | 0.040 |
Why?
|
SEER Program | 2 | 2014 | 1473 | 0.040 |
Why?
|
Receptors, Interleukin-2 | 1 | 2020 | 564 | 0.040 |
Why?
|
Survival Rate | 3 | 2021 | 12873 | 0.040 |
Why?
|
Adolescent | 3 | 2012 | 89247 | 0.040 |
Why?
|
Proportional Hazards Models | 3 | 2021 | 12563 | 0.040 |
Why?
|
Curriculum | 1 | 2012 | 3782 | 0.040 |
Why?
|
Ultrasonography, Doppler | 1 | 2020 | 463 | 0.040 |
Why?
|
Anal Canal | 1 | 2021 | 375 | 0.040 |
Why?
|
Incidence | 1 | 2016 | 21545 | 0.040 |
Why?
|
Disease-Free Survival | 2 | 2021 | 6856 | 0.040 |
Why?
|
Esophagectomy | 1 | 2020 | 482 | 0.030 |
Why?
|
Lymphatic Metastasis | 2 | 2014 | 2916 | 0.030 |
Why?
|
Diarrhea | 1 | 2023 | 1319 | 0.030 |
Why?
|
Withholding Treatment | 1 | 2020 | 620 | 0.030 |
Why?
|
Femoral Artery | 1 | 2020 | 829 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2020 | 1836 | 0.030 |
Why?
|
Immunoglobulin M | 1 | 2020 | 1528 | 0.030 |
Why?
|
Infusions, Parenteral | 1 | 2015 | 397 | 0.030 |
Why?
|
Colon | 1 | 2023 | 1804 | 0.030 |
Why?
|
Ostomy | 1 | 2014 | 33 | 0.030 |
Why?
|
Infusions, Intra-Arterial | 1 | 2014 | 221 | 0.030 |
Why?
|
Role | 1 | 2014 | 176 | 0.030 |
Why?
|
Colostomy | 1 | 2014 | 106 | 0.030 |
Why?
|
Anatomy, Cross-Sectional | 1 | 2014 | 139 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2011 | 7460 | 0.030 |
Why?
|
Yttrium Radioisotopes | 1 | 2014 | 114 | 0.030 |
Why?
|
Urban Population | 1 | 2021 | 2045 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2021 | 3629 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2021 | 2252 | 0.030 |
Why?
|
Palliative Care | 2 | 2020 | 3644 | 0.030 |
Why?
|
Antineoplastic Agents | 4 | 2015 | 13699 | 0.020 |
Why?
|
Income | 1 | 2021 | 1878 | 0.020 |
Why?
|
Thorax | 1 | 2015 | 557 | 0.020 |
Why?
|
Endoscopy, Digestive System | 1 | 2014 | 358 | 0.020 |
Why?
|
Poverty | 1 | 2003 | 2720 | 0.020 |
Why?
|
Pregnancy | 1 | 2013 | 30175 | 0.020 |
Why?
|
Societies, Medical | 1 | 2003 | 3967 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2011 | 26394 | 0.020 |
Why?
|
Anastomosis, Surgical | 1 | 2014 | 994 | 0.020 |
Why?
|
Watchful Waiting | 1 | 2014 | 498 | 0.020 |
Why?
|
Bone Marrow | 1 | 2020 | 2935 | 0.020 |
Why?
|
Markov Chains | 1 | 2014 | 979 | 0.020 |
Why?
|
Receptor, erbB-2 | 1 | 2021 | 2606 | 0.020 |
Why?
|
Antigens, CD | 1 | 2020 | 4032 | 0.020 |
Why?
|
Drug Carriers | 1 | 2014 | 710 | 0.020 |
Why?
|
Larva | 1 | 2011 | 514 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2012 | 20776 | 0.020 |
Why?
|
Hospital Costs | 1 | 2015 | 959 | 0.020 |
Why?
|
Radiotherapy | 1 | 2015 | 1506 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2014 | 2931 | 0.020 |
Why?
|
Biopsy | 1 | 2020 | 6805 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2020 | 4568 | 0.020 |
Why?
|
Child, Preschool | 1 | 2011 | 42684 | 0.020 |
Why?
|
Animals | 2 | 2016 | 169408 | 0.020 |
Why?
|
Thrombosis | 1 | 2020 | 2956 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2020 | 13020 | 0.020 |
Why?
|
Preoperative Care | 1 | 2014 | 2258 | 0.010 |
Why?
|
Embolization, Therapeutic | 1 | 2014 | 1410 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2014 | 2734 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2015 | 5323 | 0.010 |
Why?
|
Child | 1 | 2012 | 80969 | 0.010 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2016 | 2250 | 0.010 |
Why?
|
Quality of Life | 2 | 2014 | 13510 | 0.010 |
Why?
|
Postoperative Complications | 2 | 2015 | 15889 | 0.010 |
Why?
|
Young Adult | 2 | 2020 | 60110 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2014 | 15471 | 0.010 |
Why?
|
Algorithms | 1 | 2015 | 14199 | 0.010 |
Why?
|
Risk Assessment | 1 | 2014 | 24330 | 0.010 |
Why?
|
Cohort Studies | 1 | 2014 | 41800 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2016 | 21187 | 0.000 |
Why?
|